FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mirjam Crul

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Genes & Molecular Sequences

Genes, ras

Co-author Network

Publications

TOP 3
Wandena S Siegel-Lakhai; Mirjam Crul; Peter De Porre; Steven Zhang; Ilsung Chang; Henk Boot; Jos H Beijnen; Jan H M Schellens
Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function.
Jeany M Rademaker-Lakhai; Mirjam Crul; Lot Zuur; Paul Baas; Jos H Beijnen; Yvonne J W Simis; nico van zandwijk; Jan H M Schellens
Relationship between cisplatin administration and the development of ototoxicity.
Wandena S Siegel-Lakhai; Mirjam Crul; Steven Zhang; Rolf W Sparidans; Dick Pluim; A Howes; B Solanki; Jos H Beijnen; J H M Schellens
Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mirjam Crul (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2006: Wandena S Siegel-Lakhai; Mirjam Crul; Peter De Porre; Steven Zhang; Ilsung Chang; Henk Boot; Jos H Beijnen; Jan H M Schellens
Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(28):4558-64.
2006: Jeany M Rademaker-Lakhai; Mirjam Crul; Lot Zuur; Paul Baas; Jos H Beijnen; Yvonne J W Simis; nico van zandwijk; Jan H M Schellens
Relationship between cisplatin administration and the development of ototoxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(6):918-24.
2005: Wandena S Siegel-Lakhai; Mirjam Crul; Steven Zhang; Rolf W Sparidans; Dick Pluim; A Howes; B Solanki; Jos H Beijnen; J H M Schellens
Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.
British journal of cancer 2005;93(11):1222-9.
2005: Jeany M Rademaker-Lakhai; Mirjam Crul; Dick Pluim; Rolf W Sparidans; Paul Baas; Jos H Beijnen; nico van zandwijk; Jan H M Schellens
Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Anti-cancer drugs 2005;16(9):1029-36.
2004: Ellen Stokvis; Hilde Rosing; Mirjam Crul; M J Rieser; albert heck; J H M Schellens; Jos H Beijnen
Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.
Journal of mass spectrometry : JMS 2004;39(3):277-88.
2003: Mirjam Crul; Nadja E Schoemaker; Dick Pluim; Marc Maliepaard; René W M Underberg; Margaret Schot; Rolf W Sparidans; Paul Baas; Jos H Beijnen; nico van zandwijk; Jan H M Schellens
Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3526-33.
2003: Mirjam Crul; Robert C A M van Waardenburg; Suzanne Bocxe; Monique van Eijndhoven; Dick Pluim; Jos H Beijnen; Jan H M Schellens
DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin.
Biochemical pharmacology 2003;65(2):275-82.
2002: Mirjam Crul; Robert C A M van Waardenburg; Jos H Beijnen; J H M Schellens
DNA-based drug interactions of cisplatin.
Cancer treatment reviews 2002;28(6):291-303.
2002: Mirjam Crul; Laurens V Beerepoot; Ellen Stokvis; Johannes S P Vermaat; Hilde Rosing; Jos H Beijnen; Emile E Voest; Jan H M Schellens
Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518.
Cancer chemotherapy and pharmacology 2002;50(6):473-8.
2002: Rolf W Sparidans; Mirjam Crul; Jan H M Schellens; Jos H Beijnen
Isocratic ion-exchange chromatographic assay for the nucleotide gemcitabine triphosphate in human white blood cells.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;780(2):423-30.
2002: Mirjam Crul; Hilde Rosing; GJ de Klerk; Ria Dubbelman; M Traiser; S Reichert; N G Knebel; J H M Schellens; Jos H Beijnen; Wim W ten Bokkel Huinink
Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.
European journal of cancer (Oxford, England : 1990) 2002;38(12):1615-21.
2002: Mirjam Crul; GJ de Klerk; M Swart; Laura J van't Veer; Daphne de Jong; Lucie Boerrigter; Peter A Palmer; CJ Bol; H Tan; G C de Gast; Jos H Beijnen; J H M Schellens
Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(11):2726-35.
2002: Mirjam Crul; Ron A A Mathôt; Giuseppe Giaccone; Cornelis A Punt; Hilde Rosing; Michel X Hillebrand; Yoshitaka Ando; Nobosuke Nishi; Hideji Tanaka; Jan M Schellens; Jos H Beijnen
Population pharmacokinetics of the novel anticancer agent KRN7000.
Cancer chemotherapy and pharmacology 2002;49(4):287-93.
2002: Mirjam Crul; GJ de Klerk; M Swart; L Weiner; Peter A Palmer; CJ Bol; Jos H Beijnen; J H M Schellens
Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors.
European journal of drug metabolism and pharmacokinetics 2002;27(1):61-5.
2001: Mirjam Crul; GJ de Klerk; Jos H Beijnen; J H M Schellens
Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
Anti-cancer drugs 2001;12(3):163-84.
1997: Mirjam Crul; J H M Schellens; Jos H Beijnen; Marc Maliepaard
Cisplatin resistance and DNA repair.
Cancer treatment reviews 1997;23(5-6):341-66.